You can buy or sell Biogen and other stocks, options, ETFs, and crypto commission-free!
Biogen Inc. Common Stock, also called Biogen, is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Read More It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Biogen announces $5 billion buyback days after shelving Alzheimer's trials
(Reuters) - Biogen Inc said on Monday it would buy back shares worth $5 billion, days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.
Biogen OKs $5B share buyback plan
The board of Biogen (NASDAQ:BIIB) has authorized a $5B Share Repurchase Program, in addition to the ~$1.7B remaining under the program announced in August 2018. Shares are up 2% premarket....
Available Apr 24, Pre-Market